Bret Jensen

Apple Inc.’s valuation is substantially higher than its 10-year average and any risk premium to justify holding the stock has disappeared. Learn more on AAPL stock here.

Pulmonx Corporation is likely to remain unprofitable for several years. Read more to see a detailed analysis on LUNG stock.

The S&P 500 is overvalued given potential for recession in 2024 and current valuations. Find out 3 potential triggers for a recession and a bear market in 2024.

Twist Bioscience recently signed collaboration deals with 2 new drugmakers and saw upward analyst price target revisions after Q2. Read more on TWST stock here.

Cantaloupe is delivering solid revenue growth, becoming increasingly profitable, and stock has seen some insider buying of late. Read more on CTLP stock here.

Amicus Therapeutics, Inc. is a biotech company developing therapies for rare diseases. Click here to read my analysis on FOLD stock now.

Changes in the Fed Funds rate have accurately predicted subsequent stock market movements, albeit with a lag, for generations. Read more on SPY ETF here.

Equities have now pulled back some 10% since the start of August. Click here to find out the three things that need to happen before getting bullish on equities.

Despite stellar revenue growth, Inspire Medical Systems stock has fallen more than 50% from recent highs this summer. Read more to see our analysis on INSP.

Collegium Pharmaceutical, Inc. stock is cheap based on FY2024 profit estimates. Read more to see a detailed analysis on COLL stock.